MetLife Investment Management’s Harvard Bioscience HBIO Stock Holding History

MetLife Investment Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,115	Closed	-$89.7K	–	2900
2024 Q1	$89.7K	Buy	2,115 +35	+2%	+$1.57K	﹤0.01%	2583
2023 Q4	$111K	Hold	2,080	–	–	﹤0.01%	2558
2023 Q3	$89.4K	Hold	2,080	–	–	﹤0.01%	2627
2023 Q2	$114K	Buy	+2,080	New	+$114K	﹤0.01%	2595
2022 Q2	–	Sell	-1,684	Closed	-$105K	–	2879
2022 Q1	$105K	Buy	1,684 +201	+14%	+$11.9K	﹤0.01%	2614
2021 Q4	$105K	Hold	1,483	–	–	﹤0.01%	2393
2021 Q3	$103K	Buy	+1,483	New	+$118K	﹤0.01%	2429

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

MetLife Investment Management's HBIO Position: Q2 2024 in Review

MetLife Investment Management sold out of Harvard Bioscience (HBIO) in Q2 2024, closing a stake of 2,115 shares — an estimated $89.7K sold.

MetLife Investment Management first reported a position in HBIO in Q3 2021 and held it in 7 quarters. The position peaked at $114K in Q2 2023. 100 funds tracked by Wall St. Rank hold HBIO as of Q2 2024.

MetLife Investment Management reported no remaining Harvard Bioscience position as of Q2 2024 after selling out during the quarter.
MetLife Investment Management sold 2,115 Harvard Bioscience shares in Q2 2024, an estimated $89.7K.
MetLife Investment Management first reported a position in Harvard Bioscience in Q3 2021 and held it in 7 quarters.
MetLife Investment Management's Harvard Bioscience position peaked at $114K in Q2 2023.
100 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2024.

Based on MetLife Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.